Our study moves from the previous research conducted by Ciregia which, however, was limited to only a couple of monozygotic twins discordant for CFS. The study of 2013 pointed out some proteins which are useful both to define a panel of potential diagnostic biomarkers and to shed new light on the comprehension of the pathogenetic pathways of CFS [136].
Our research was born, then, from the need to extend the results obtained from the twin study on a larger number of subjects with similar medical history and continue the search for biomarkers useful for both diagnosis and therapy of this syndrome.
Using different techniques (2-DE; western blot and ELISA – kit ), with a proteomic approach, we tried to confirm the biomarkers found in past studies and to seek new ones
